Disruption of TET2 promotes the therapeutic efficacy o

Nature 558, 307-312 DOI: 10.1038/s41586-018-0178-z

Citation Report

#	Article	IF	CITATIONS
1	Current development of chimeric antigen receptor T-cell therapy. Stem Cell Investigation, 2018, 5, 44-44.	3.0	26
2	Making CAR T Cells a Solid Option for Solid Tumors. Frontiers in Immunology, 2018, 9, 2593.	4.8	147
3	Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2018, 11, 130.	17.0	25
4	Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. Cell, 2018, 175, 1958-1971.e15.	28.9	378
5	Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. Cell Stem Cell, 2018, 23, 850-858.e4.	11.1	110
6	Illuminating the genome-wide activity of genome editors for safe and effective therapeutics. Genome Biology, 2018, 19, 226.	8.8	28
7	Universal CARs, universal T cells, and universal CAR T cells. Journal of Hematology and Oncology, 2018, 11, 132.	17.0	184
8	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Frontiers in Immunology, 2018, 9, 2740.	4.8	58
9	Versatile targeting system for lentiviral vectors involving biotinylated targeting molecules. Virology, 2018, 525, 170-181.	2.4	6
10	Cytokine release syndrome: grading, modeling, and new therapy. Journal of Hematology and Oncology, 2018, 11, 121.	17.0	99
11	The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1573-1584.	2.0	16
12	Allogeneic CAR-T Cells: More than Ease of Access?. Cells, 2018, 7, 155.	4.1	129
13	A CHIP mutation to battle cancer: potential or hazard for cardiovascular disease?. Cardiovascular Research, 2018, 114, e96-e98.	3.8	0
14	T lymphocytes as therapeutic arsenal for patients with hematological malignancies. Current Opinion in Oncology, 2018, 30, 425-434.	2.4	4
15	Success stories. Nature Reviews Cancer, 2018, 18, 465-465.	28.4	0
16	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Frontiers in Immunology, 2018, 9, 1740.	4.8	155
17	Tumour tamed by transfer of one T cell. Nature, 2018, 558, 193-195.	27.8	2
18	CRISPR: Stressed about p53?. Trends in Molecular Medicine, 2018, 24, 731-733.	6.7	8

#	Article	lF	CITATIONS
19	State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. , 2019, 7, 202.		48
20	Chemical probes for spatially resolved measurement of active enzymes in single cells. Methods in Enzymology, 2019, 628, 243-262.	1.0	4
21	Cellular Therapy for Melanoma. , 2019, , 1-33.		0
22	Application of CAR T cells for the treatment of solid tumors. Progress in Molecular Biology and Translational Science, 2019, 164, 293-327.	1.7	15
23	T cell receptorâ€based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunological Reviews, 2019, 290, 127-147.	6.0	180
24	Updates on CAR Tâ€cell therapy in Bâ€cell malignancies. Immunological Reviews, 2019, 290, 39-59.	6.0	61
25	Immunobiology of chimeric antigen receptor T cells and novel designs. Immunological Reviews, 2019, 290, 100-113.	6.0	16
26	The Human TET2 Gene Contains Three Distinct Promoter Regions With Differing Tissue and Developmental Specificities. Frontiers in Cell and Developmental Biology, 2019, 7, 99.	3.7	8
27	Gene editing: Towards the third generation of adoptive T-cell transfer therapies. Immuno-Oncology Technology, 2019, 1, 19-26.	0.3	7
28	Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2019, 10, 1342.	4.8	33
29	Transfection with Nanostructure Electroâ€Injection is Minimally Perturbative. Advanced Therapeutics, 2019, 2, 1900133.	3.2	30
30	Clonal hematopoiesis in human aging and disease. Science, 2019, 366, .	12.6	590
31	Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. , 2019, 7, 276.		101
32	Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. Frontiers in Cell and Developmental Biology, 2019, 7, 207.	3.7	32
33	Opportunities and Challenges for Antibodies against Intracellular Antigens. Theranostics, 2019, 9, 7792-7806.	10.0	15
34	Evidence of longâ€lasting antiâ€CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. Hematological Oncology, 2019, 37, 601-608.	1.7	36
35	Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 2019, 20, 4315.	4.1	21
36	Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies. Blood, 2019, 134, 1203-1213.	1.4	74

#	ARTICLE	IF	CITATIONS
37	Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine, 2019, 25, 1341-1355.	30.7	400
38	Engineered T Cell Therapy for Cancer in the Clinic. Frontiers in Immunology, 2019, 10, 2250.	4.8	267
39	CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV. Frontiers in Immunology, 2019, 10, 2310.	4.8	26
40	iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. Genome Biology, 2019, 20, 14.	8.8	45
41	CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Frontiers in Immunology, 2019, 10, 128.	4.8	568
42	CAR-T immunotherapies: Biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering. Biotechnology Advances, 2019, 37, 107411.	11.7	12
43	Pharmacoepigenetic Processors: Epigenetic Drugs, Drug Resistance, Toxicoepigenetics, and Nutriepigenetics. , 2019, , 191-424.		9
44	Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression. Science Translational Medicine, 2019, 11, .	12.4	100
45	Gene Transfer to HSCs: Finding the Leukemia in Murine Leukemia Viruses. Molecular Therapy, 2019, 27, 1072-1073.	8.2	0
46	Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir. Current Opinion in Virology, 2019, 38, 21-30.	5.4	28
47	Gene editing for immune cell therapies. Nature Biotechnology, 2019, 37, 1425-1434.	17.5	147
48	TET2 missense variants in human neoplasia. A proposal of structural and functional classification. Molecular Genetics & Genomic Medicine, 2019, 7, e00772.	1.2	9
49	Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells, 2019, 8, 472.	4.1	122
50	Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nature Reviews Cancer, 2019, 19, 339-348.	28.4	35
51	Chimeric antigen receptor T cell persistence and memory cell formation. Immunology and Cell Biology, 2019, 97, 664-674.	2.3	142
52	TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair. Frontiers in Oncology, 2019, 9, 210.	2.8	72
53	CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. International Journal of Molecular Sciences, 2019, 20, 1903.	4.1	15
54	Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque. Molecular Therapy, 2019, 27, 1074-1086.	8.2	34

#	Article	IF	CITATIONS
55	Role of tenâ€eleven translocation proteins and 5â€hydroxymethylcytosine in hepatocellular carcinoma. Cell Proliferation, 2019, 52, e12626.	5.3	26
57	Nonâ€viral gene delivery for cancer immunotherapy. Journal of Gene Medicine, 2019, 21, e3092.	2.8	22
58	Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives. Archives of Pharmacal Research, 2019, 42, 607-616.	6.3	36
59	Mechanisms of resistance to CAR T cell therapy. Nature Reviews Clinical Oncology, 2019, 16, 372-385.	27.6	518
60	In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function. Journal of Visualized Experiments, 2019, , .	0.3	19
61	TET Enzymes and 5hmC in Adaptive and Innate Immune Systems. Frontiers in Immunology, 2019, 10, 210.	4.8	102
62	The Emergence of Universal Immune Receptor T Cell Therapy for Cancer. Frontiers in Oncology, 2019, 9, 176.	2.8	64
63	The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. Trends in Immunology, 2019, 40, 292-309.	6.8	61
64	Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. Nature Reviews Drug Discovery, 2019, 18, 447-462.	46.4	141
65	Treg programming and therapeutic reprogramming in cancer. Immunology, 2019, 157, 198-209.	4.4	46
66	Proposal for the International Society for Cell & Gene Therapy position statement on assays for the quality control and potency assessment of adoptive cellular immunotherapies. Cytotherapy, 2019, 21, 367-375.	0.7	3
67	Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Cytotherapy, 2019, 21, 593-602.	0.7	30
68	Engineering for Success: Approaches to Improve Chimeric Antigen Receptor TÂCell Therapy for Solid Tumors. Drugs, 2019, 79, 401-415.	10.9	17
69	Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma. Frontiers in Oncology, 2019, 9, 69.	2.8	68
70	Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies. Cancers, 2019, 11, 191.	3.7	33
71	Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Advances, 2019, 3, 2317-2322.	5.2	69
72	c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature, 2019, 576, 293-300.	27.8	480
73	Escape From ALL-CARTaz. Cancer Journal (Sudbury, Mass), 2019, 25, 217-222.	2.0	20

#	Article	IF	CITATIONS
74	Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 6223.	4.1	88
75	T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments. Current Opinion in Oncology, 2019, 31, 430-438.	2.4	6
76	Understanding and Modulating Immunity With Cell Reprogramming. Frontiers in Immunology, 2019, 10, 2809.	4.8	13
77	Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. Frontiers in Oncology, 2019, 9, 1237.	2.8	106
78	Orthotopic editing of T-cell receptors. Nature Biomedical Engineering, 2019, 3, 949-950.	22.5	0
79	Enabling drug discovery and development through single-cell imaging. Expert Opinion on Drug Discovery, 2019, 14, 115-125.	5.0	9
80	Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. Clinical Chemistry, 2019, 65, 519-529.	3.2	4
81	A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. Clinical Cancer Research, 2019, 25, 2096-2108.	7.0	69
82	Advances in Chimeric Antigen Receptor T ell Therapies for Solid Tumors. Clinical Pharmacology and Therapeutics, 2019, 105, 71-78.	4.7	22
83	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clinical Cancer Research, 2019, 25, 2042-2048.	7.0	77
84	CARâ€T cells beyond CD19, UnCARâ€Ted territory. American Journal of Hematology, 2019, 94, S34-S41.	4.1	6
85	Allogeneic CAR T cell therapies for leukemia. American Journal of Hematology, 2019, 94, S50-S54.	4.1	55
86	CAR T cell therapy: inroads to response and resistance. Nature Reviews Immunology, 2019, 19, 73-74.	22.7	148
87	T-cells "à la CAR-T(e)―– Genetically engineering T-cell response against cancer. Advanced Drug Delivery Reviews, 2019, 141, 23-40.	13.7	17
88	Immunotherapy in pancreatic cancer: New hope or mission impossible?. Cancer Letters, 2019, 445, 57-64.	7.2	26
89	Emerging Cellular Therapies for Cancer. Annual Review of Immunology, 2019, 37, 145-171.	21.8	263
90	Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. , 2020, 205, 107419.		81
91	Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic. Molecular Therapy, 2020, 28, 64-74.	8.2	50

#	Article	IF	CITATIONS
93	Determinants of response and resistance to CAR T cell therapy. Seminars in Cancer Biology, 2020, 65, 80-90.	9.6	59
94	Retroviral Insertional Mutagenesis in Humans: Evidence for Four Genetic Mechanisms Promoting Expansion of Cell Clones. Molecular Therapy, 2020, 28, 352-356.	8.2	78
95	Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nature Communications, 2020, 11, 219.	12.8	167
96	The forces driving clonal expansion of the HIV-1 latent reservoir. Virology Journal, 2020, 17, 4.	3.4	53
98	TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product. Molecular Therapy, 2020, 28, 561-571.	8.2	10
99	Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nature Biomedical Engineering, 2020, 4, 69-83.	22.5	415
100	Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 2020, 17, 147-167.	27.6	786
101	â€~Off-the-shelf' allogeneic CAR T cells: development and challenges. Nature Reviews Drug Discovery, 2020, 19, 185-199.	46.4	632
102	AAVS1 siteâ€ s pecific integration of the CAR gene into human primary T cells using a linear closedâ€ended AAVâ€based DNA vector. Journal of Gene Medicine, 2020, 22, e3157.	2.8	4
103	Assessment of memory formation by metabolically engineered antigen-specific CD8 T cells. Methods in Enzymology, 2020, 631, 77-90.	1.0	0
104	Clonal hematopoiesis as a model for premalignant changes during aging. Experimental Hematology, 2020, 83, 48-56.	0.4	56
105	Brain immunology and immunotherapy in brain tumours. Nature Reviews Cancer, 2020, 20, 12-25.	28.4	389
106	CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges. Briefings in Functional Genomics, 2020, 19, 183-190.	2.7	4
107	Epigenetic Regulation of T Cell Memory: Recalling Therapeutic Implications. Trends in Immunology, 2020, 41, 29-45.	6.8	46
108	The future of cellular immunotherapy for childhood leukemia. Current Opinion in Pediatrics, 2020, 32, 13-25.	2.0	13
109	Regulatory Issues in Gene-Modified Immune Effector Cell Therapy. , 2020, , 209-222.		2
110	CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?. Molecular Therapy, 2020, 28, 2320-2339.	8.2	194
111	CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer. Frontiers in Immunology, 2020, 11, 2062.	4.8	45

ARTICLE IF CITATIONS # Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future 2.8 46 112 Directions. Frontiers in Oncology, 2020, 10, 1594. Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T 3.3 29 cell therapy. Scientific Reports, 2020, 10, 17753. <scp>TET</scp> 2 promotes antiâ€tumor immunity by governing G―<scp>MDSC</scp> s and <scp>CD</scp> 114 4.5 25 8 ⁺ Tâ€cell numbers. EMBO Reports, 2020, 21, e49425. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nature Medicine, 2020, 26, 1878-1887. T cell receptor therapy against melanomaâ€"Immunotherapy for the future?. Scandinavian Journal of 116 2.7 8 Immunology, 2020, 92, e12927. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child 12.8 with metastatic rhabdomyosarcoma. Nature Communications, 2020, 11, 3549. Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kineticâ€Pharmacodynamic Modeling 118 2.0 28 Approaches. Journal of Clinical Pharmacology, 2020, 60, S147-S159. Tet2 at the interface between cancer and immunity. Communications Biology, 2020, 3, 667. 4.4 Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable 120 14.3 83 Antitumor Efficacy. Immunity, 2020, 53, 456-470.e6. Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. Cancers, 2020, 12, 121 2175. The Chimeric Antigen Receptor Detection Toolkit. Frontiers in Immunology, 2020, 11, 1770. 122 4.8 34 CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. Frontiers in Oncology, 2020, 2.8 10, 1243. The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies. Cancers, 124 3.7 19 2020, 12, 2030. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. 17.1 84 Signal Transduction and Targeted Therapy, 2020, 5, 134. TET family dioxygenases and the TET activator vitamin C in immune responses and cancer. Blood, 2020, 126 1.4 40 136, 1394-1401. Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell, 2020, 38, 473-488. 127 16.8 342 IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment 128 8.2 49 of Solid Tumors. Molecular Therapy, 2020, 28, 2379-2393. 129 Clonal hematopoiesis and non-hematologic disorders. Blood, 2020, 136, 1606-1614. 1.4

#	Article	IF	CITATIONS
130	A brief review concerning Chimeric Antigen Receptors T cell therapy. Journal of Cancer, 2020, 11, 5424-5431.	2.5	4
131	Improving CAR T-cells: The next generation. Seminars in Hematology, 2020, 57, 115-121.	3.4	13
132	Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors. Frontiers in Immunology, 2020, 11, 594609.	4.8	66
133	Metabolic and epigenetic regulation of T-cell exhaustion. Nature Metabolism, 2020, 2, 1001-1012.	11.9	167
134	Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors. Immunological Reviews, 2020, 298, 117-133.	6.0	9
135	Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nature Communications, 2020, 11, 4810.	12.8	95
136	The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome. Blood Advances, 2020, 4, 4483-4493.	5.2	24
137	The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. Cell Communication and Signaling, 2020, 18, 134.	6.5	28
138	Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery, 2020, 19, 776-800.	46.4	264
139	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. Frontiers in Immunology, 2020, 11, 1689.	4.8	63
140	Overhauling CAR T Cells to Improve Efficacy, Safety and Cost. Cancers, 2020, 12, 2360.	3.7	9
141	Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy. Frontiers in Immunology, 2020, 11, 581116.	4.8	2
142	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science, 2020, 370, 1328-1334.	12.6	273
143	Engineering better chimeric antigen receptor T cells. Experimental Hematology and Oncology, 2020, 9, 34.	5.0	64
144	Precision Tools in Immuno-Oncology: Synthetic Gene Circuits for Cancer Immunotherapy. Vaccines, 2020, 8, 732.	4.4	4
145	Circles of Life: linking metabolic and epigenetic cycles to immunity. Immunology, 2020, 161, 165-174.	4.4	23
146	T Cell Receptor Engineered Lymphocytes for Cancer Therapy. Current Protocols in Immunology, 2020, 129, e97.	3.6	7
147	Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. Nature Communications, 2020, 11, 2246.	12.8	20

#	Article	IF	CITATIONS
148	CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome. , 2020, 8, e000364.		14
149	T-cell lymphoma secondary to checkpoint inhibitor therapy. , 2020, 8, e000104.		25
150	p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy. Cancer Cell, 2020, 37, 756-758.	16.8	3
151	CAR T cell therapy: newer approaches to counter resistance and cost. Heliyon, 2020, 6, e03779.	3.2	19
152	CRISPR screen in mechanism and target discovery for cancer immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188378.	7.4	25
153	Nanopore sequencing as a scalable, cost-effective platform for analyzing polyclonal vector integration sites following clinical T cell therapy. , 2020, 8, e000299.		5
154	Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy. Cells, 2020, 9, 1485.	4.1	48
155	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer, 2020, 146, 174-181.	2.0	8
156	Orthotopic T-Cell Receptor Replacement—An "Enabler―for TCR-Based Therapies. Cells, 2020, 9, 1367.	4.1	12
157	Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. Blood, 2020, 136, 1055-1066.	1.4	58
158	Advances in Developing CAR T-Cell Therapy for HIV Cure. Frontiers in Immunology, 2020, 11, 361.	4.8	42
159	Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology. Annual Review of Cancer Biology, 2020, 4, 121-139.	4.5	13
160	grabseqs: simple downloading of reads and metadata from multiple next-generation sequencing data repositories. Bioinformatics, 2020, 36, 3607-3609.	4.1	11
161	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.5	12
162	Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer. Cancers, 2020, 12, 842.	3.7	21
163	Next-generation CAR T cells to overcome current drawbacks. International Journal of Hematology, 2020, 114, 532-543.	1.6	7
164	Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors. Journal of Leukocyte Biology, 2020, 108, 1067-1079.	3.3	50
165	Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity. Experimental Hematology, 2020, 83, 85-94.	0.4	77

		CITATION REPORT	
#	Article	IF	CITATIONS
166	The Contribution of Epigenetics to Cancer Immunotherapy. Trends in Immunology, 2020, 41, 676-691.	6.8	133
167	Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy. Trends in Immunology, 2020, 41, 665-675.	6.8	42
168	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro-Oncology, 2020, 22, 1425-1438.	1.2	37
169	Cancer immunotherapy comes of age and looks for maturity. Nature Communications, 2020, 11, 3325.	12.8	93
170	Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5442-5452.	7.1	34
171	Somatic mutations and T-cell clonality in patients with immunodeficiency. Haematologica, 2020, 105, 2757-2768.	3.5	18
172	Adoptive T-cell therapy for HBV-associated HCC and HBV infection. Antiviral Research, 2020, 176, 104748.	4.1	31
173	All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. Current Opinion in Biotechnology, 2020, 65, 75-87.	6.6	33
174	Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology, 2020, 158, 2250-2265.e20.	1.3	97
175	A general mathematical framework for understanding the behavior of heterogeneous stem cell regeneration. Journal of Theoretical Biology, 2020, 492, 110196.	1.7	10
176	Epigenetics of T cell fate decision. Current Opinion in Immunology, 2020, 63, 43-50.	5.5	21
177	Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. Briefings in Functional Genomics, 2020, 19, 175-182.	2.7	59
178	Cancer immunotherapy: Pros, cons and beyond. Biomedicine and Pharmacotherapy, 2020, 124, 109821.	5.6	337
179	Engineering T cells for immunotherapy of primary human hepatocellular carcinoma. Journal of Genetics and Genomics, 2020, 47, 1-15.	3.9	15
180	Bâ€cell maturation antigenâ€specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. International Journal of Cancer, 2020, 147, 2029-2041.	5.1	10
181	The Emerging Landscape of Immune Cell Therapies. Cell, 2020, 181, 46-62.	28.9	247
182	Enhancing CAR T cell efficacy: the next step toward a clinical revolution?. Expert Review of Hematology, 2020, 13, 533-543.	2.2	10
183	Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cellâ€derived anti–glypicanâ€3 chimeric antigen receptorâ€expressing natural killer/innate lymphoid cells. Cancer Science, 2020, 111, 1478-1490.	3.9	74

#	Article	IF	CITATIONS
184	Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. Clinical and Experimental Medicine, 2020, 20, 469-480.	3.6	8
185	Light-Activatable TET-Dioxygenases Reveal Dynamics of 5-Methylcytosine Oxidation and Transcriptome Reorganization. Journal of the American Chemical Society, 2020, 142, 7289-7294.	13.7	12
186	Stem cell donors should not be screened for clonal hematopoiesis. Blood Advances, 2020, 4, 789-792.	5.2	27
187	Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation. Haematologica, 2021, 106, 847-858.	3.5	46
188	Clonal Hematopoiesis–Driver DNMT3A Mutations Alter Immune Cells in Heart Failure. Circulation Research, 2021, 128, 216-228.	4.5	129
189	Toward Better Understanding and Management of CAR-T Cell–Associated Toxicity. Annual Review of Medicine, 2021, 72, 365-382.	12.2	34
190	Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Critical Reviews in Oncology/Hematology, 2021, 157, 103096.	4.4	10
191	CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma. Clinical Cancer Research, 2021, 27, 473-484.	7.0	68
192	Pharmacology of Chimeric Antigen Receptor–Modified T Cells. Annual Review of Pharmacology and Toxicology, 2021, 61, 805-829.	9.4	7
193	Clonal tracking of haematopoietic cells: insights and clinical implications. British Journal of Haematology, 2021, 192, 819-831.	2.5	10
194	Tools for experimental and computational analyses of off-target editing by programmable nucleases. Nature Protocols, 2021, 16, 10-26.	12.0	52
195	Addressing Patient to Patient Variability for Autologous CAR T Therapies. Journal of Pharmaceutical Sciences, 2021, 110, 1871-1876.	3.3	12
196	Efficient Editing of an Adenoviral Vector Genome with CRISPR/Cas9. Indian Journal of Microbiology, 2021, 61, 91-95.	2.7	1
197	Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nature Reviews Cancer, 2021, 21, 145-161.	28.4	436
198	Harnessing Alternative Substrates to Probe TET Family Enzymes. Methods in Molecular Biology, 2021, 2272, 265-280.	0.9	1
199	Treatment and resistance of glioblastoma to CAR T-cell immunotherapies. , 2021, , 453-471.		0
200	Genome editing approaches to Î ² -hemoglobinopathies. Progress in Molecular Biology and Translational Science, 2021, 182, 153-183.	1.7	13
201	IFN Signaling and Myeloid Cells in the Setting of CAR T: A Central Role for the Induction of Endogenous Anti-tumor Immunity. , 2021, 18, .		0

ARTICLE IF CITATIONS # Synthetic genomics for curing genetic diseases. Progress in Molecular Biology and Translational 202 1.7 0 Science, 2021, 182, 477-520. Tet methylcytosine dioxygenase 2 suppresses renal cell cancer proliferation and metastasis by regulating the miR-200c-SCD axis. Biocell, 2021, 45, 599-615. NPM–ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and 204 0.9 10 Malignant Transformation. Cancer Research, 2021, 81, 3241-3254. Adoptive Immunotherapy beyond CAR T-Cells. Cancers, 2021, 13, 743. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for 206 9.4 12 Cancer. Cancer Discovery, 2021, 11, 560-574. CRISPR Takes the Front Seat in CART-Cell Development. BioDrugs, 2021, 35, 113-124. 4.6 208 Epigenetic regulation of T cell adaptive immunity. Immunological Reviews, 2021, 300, 9-21. 6.0 16 Antigen-driven clonal selection shapes the persistence of HIV-1–infected CD4+ T cells in vivo. Journal 209 8.2 of Clinical Investigation, 2021, 131, . T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation 210 3.7 19 Strategies. Cancers, 2021, 13, 598. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies. BioMed Research 211 International, 2021, 2021, 1-8. Genetic engineering of T cells for immunotherapy. Nature Reviews Genetics, 2021, 22, 427-447. 212 16.363 Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes. Cancer Research, 2021, 81, 1965-1976. Hallmarks of the aging Tâ€cell system. FEBS Journal, 2021, 288, 7123-7142. 214 4.7 70 Frequent somatic <i>TET2</i> mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. Blood, 2021, 138, 662-673. 1.4 Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma. 216 4.8 64 Frontiers in Immunology, 2021, 12, 640082. InÂvivo CRISPR screening reveals nutrient signaling processes underpinning CD8+ TÂcell fate decisions. 28.9 Cell, 2021, 184, 1245-1261.e21. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CARâ€"T-cell responses 218 1.4 28 against ALL. Blood, 2021, 138, 122-135. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. Frontiers in 219 4.8 Immunology, 2021, 12, 652160.

#	Article	IF	CITATIONS
220	Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. Leukemia, 2021, 35, 1365-1379.	7.2	41
221	Improving and Maintaining Responses in Pediatric B–Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor–T Cell Therapy. Cancer Journal (Sudbury, Mass), 2021, 27, 151-158.	2.0	0
222	Challenges and Solutions to Bringing Chimeric Antigen Receptor T-Cell Therapy to Myeloid Malignancies. Cancer Journal (Sudbury, Mass), 2021, 27, 143-150.	2.0	0
223	Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model. Frontiers in Immunology, 2021, 12, 628906.	4.8	31
224	A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3–Specific CAR T Cells in Solid Tumors. Clinical Cancer Research, 2021, 27, 3757-3771.	7.0	25
225	CAR-T cells and BiTEs in solid tumors: challenges and perspectives. Journal of Hematology and Oncology, 2021, 14, 65.	17.0	50
226	Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma. Blood Cancer Discovery, 2021, 2, 302-318.	5.0	40
227	Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job. Current Hematologic Malignancy Reports, 2021, 16, 218-233.	2.3	4
228	Mechanisms of response and resistance to CAR T cell therapies. Current Opinion in Immunology, 2021, 69, 56-64.	5.5	18
229	Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science, 2021, 372, .	12.6	297
230	Clonal haematopoiesis of emerging significance. Pathology, 2021, 53, 300-311.	0.6	9
231	Cellular networks controlling T cell persistence in adoptive cell therapy. Nature Reviews Immunology, 2021, 21, 769-784.	22.7	83
232	Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 2021, 22, 5536.	4.1	17
233	Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nature Cancer, 2021, 2, 629-642.	13.2	59
234	Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. Expert Opinion on Therapeutic Targets, 2021, 25, 347-363.	3.4	25
235	TET2 Inhibits PD-L1 Gene Expression in Breast Cancer Cells through Histone Deacetylation. Cancers, 2021, 13, 2207.	3.7	19
236	Multiple Genes Surrounding <i>Bcl-x_L</i> , a Common Retroviral Insertion Site, Can Influence Hematopoiesis Individually or in Concert. Human Gene Therapy, 2021, 32, 458-472.	2.7	4
237	How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications. Trends in Immunology, 2021, 42, 401-417.	6.8	18

#	Article	IF	CITATIONS
238	Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. Journal of Hematology and Oncology, 2021, 14, 73.	17.0	135
240	Delivery technologies for T cell gene editing: Applications in cancer immunotherapy. EBioMedicine, 2021, 67, 103354.	6.1	48
241	Investigation of product-derived lymphoma following infusion of <i>piggyBac</i> -modified CD19 chimeric antigen receptor T cells. Blood, 2021, 138, 1391-1405.	1.4	87
242	A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. Frontiers in Oncology, 2021, 11, 664421.	2.8	20
243	Retrieval of vector integration sites from cell-free DNA. Nature Medicine, 2021, 27, 1458-1470.	30.7	26
244	Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies. Current Medical Science, 2021, 41, 420-430.	1.8	5
245	CAR TÂcells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice. Cell Reports Medicine, 2021, 2, 100297.	6.5	18
246	A Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2021, 22, 6371.	4.1	8
247	Flow cytometry data mining by cytoChain identifiesÂdeterminants of exhaustion and stemness in TCRâ€engineered T cells. European Journal of Immunology, 2021, 51, 1992-2005.	2.9	10
248	Role of Tet2 in Regulating Adaptive and Innate Immunity. Frontiers in Cell and Developmental Biology, 2021, 9, 665897.	3.7	8
249	Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents. Cancers, 2021, 13, 3236.	3.7	3
250	Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia. Expert Opinion on Investigational Drugs, 2021, 30, 773-784.	4.1	8
251	Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. Bone Marrow Transplantation, 2021, 56, 2630-2636.	2.4	11
252	Non-viral transfection technologies for next-generation therapeutic T cell engineering. Biotechnology Advances, 2021, 49, 107760.	11.7	33
253	Exploiting Single-Cell Tools in Gene and Cell Therapy. Frontiers in Immunology, 2021, 12, 702636.	4.8	21
254	Clonal hematopoiesis and its emerging effects on cellular therapies. Leukemia, 2021, 35, 2752-2758.	7.2	21
255	Exosomal delivery of therapeutic modulators through the blood–brain barrier; promise and pitfalls. Cell and Bioscience, 2021, 11, 142.	4.8	70
256	Early-phenotype CAR-T cells for the treatment of pediatric cancers. Annals of Oncology, 2021, 32, 1366-1380.	1.2	14

		Citation R	EPORT	
#	Article		IF	CITATIONS
257	Engineering-enhanced CAR T cells for improved cancer therapy. Nature Cancer, 2021, 2	2, 780-793.	13.2	60
258	Targeted TÂcell receptor gene editing provides predictable TÂcell product function for Cell Reports Medicine, 2021, 2, 100374.	mmunotherapy.	6.5	30
260	Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. Leu Lymphoma, 2021, 62, 3333-3347.	kemia and	1.3	2
261	Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy. Blood Cancer Disco 408-422.	very, 2021, 2,	5.0	84
262	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blo 2021, 5, 2982-2986.	od Advances,	5.2	45
263	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and exhausted T cells in chronic lymphocytic leukemia. Journal of Clinical Investigation, 202	reinvigorates 1, 131, .	8.2	45
264	Clonal hematopoiesis and associated diseases: A review of recent findings. Cancer Scie 3962-3971.	nce, 2021, 112,	3.9	40
265	A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using modified T cells. Journal of Clinical Investigation, 2021, 131, .	genetically	8.2	12
266	Epigenetic strategies to boost CAR TÂcell therapy. Molecular Therapy, 2021, 29, 2640-	2659.	8.2	21
267	Two cases of TÂcell lymphoma following Piggybac-mediated CAR TÂcell therapy. Molec 29, 2631-2633.	ular Therapy, 2021,	8.2	10
268	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy ir Malignancies. Journal of the National Cancer Institute, 2022, 114, 436-445.	1 B-Cell	6.3	29
269	BACH2 is a putative T cell lymphoma tumor suppressor that may play a role in product- cell lymphomas. Blood, 2021, , .	derived CAR-T	1.4	4
270	Single-cell technologies to dissect heterogenous immune cell therapy products. Curren Biomedical Engineering, 2021, 20, 100343.	t Opinion in	3.4	1
271	Individual cellâ€based modeling of tumor cell plasticityâ€induced immune escape after Computational and Systems Oncology, 2021, 1, e21029.	CARâ€T therapy.	1.5	1
272	Advances in engineering and synthetic biology toward improved therapeutic immune c Opinion in Biomedical Engineering, 2021, 20, 100342.	ells. Current	3.4	2
273	Broadly neutralizing antibody–derived CAR T cells reduce viral reservoir in individuals HIV-1. Journal of Clinical Investigation, 2021, 131, .	infected with	8.2	38
274	Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and perspectives. Cancer Treatment Reviews, 2021, 100, 102288.	future	7.7	9
275	Genome editing of therapeutic T cells. Gene and Genome Editing, 2021, 2, 100010.		2.6	1

#	Article	IF	Citations
276	Epigenetic programming of the immune responses in cancer. , 2022, , 197-235.		1
277	Engineering solutions to design CAR-T cells. , 2022, , 1-31.		0
278	Oxygen regulation of TET enzymes. FEBS Journal, 2021, 288, 7143-7161.	4.7	20
279	The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells. Nature Communications, 2021, 12, 472.	12.8	23
280	Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology, 2021, 18, 199-214.	27.6	179
281	Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies. Methods in Molecular Biology, 2020, 2086, 203-211.	0.9	7
282	Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy. Methods in Molecular Biology, 2020, 2115, 419-433.	0.9	8
283	Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview. Methods in Molecular Biology, 2021, 2174, 219-244.	0.9	7
284	Chimeric Antigen Receptor (CAR) Redirected T Cells. Learning Materials in Biosciences, 2021, , 251-302.	0.4	1
285	Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms. Cellular and Molecular Immunology, 2020, 17, 576-586.	10.5	12
291	CD4 + T cells support polyfunctionality of cytotoxic CD8 + T cells with memory potential in immunological control of tumor. Cancer Science, 2020, 111, 1958-1968.	3.9	19
292	Assessment of HIV-1 integration in tissues and subsets across infection stages. JCI Insight, 2020, 5, .	5.0	12
293	Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. Journal of Clinical Investigation, 2019, 129, 988-998.	8.2	209
294	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. Journal of Clinical Investigation, 2019, 130, 673-685.	8.2	78
295	Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities. Journal of Clinical Investigation, 2020, 130, 6021-6033.	8.2	102
296	Loss Of Tet2 ÂIn T Cells Drives Translocated Pathobiont Derived Aryl Hydrocarbon Receptor Agonist-Induced Tc1 Cell Autoimmune Hepatitis. SSRN Electronic Journal, 0, , .	0.4	0
297	Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells. Human Gene Therapy, 2021, 32, 1044-1058.	2.7	35
298	Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. Cancers, 2021, 13, 4986.	3.7	6

#	Article	IF	CITATIONS
299	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. Transplantation and Cellular Therapy, 2022, 28, 5-17.	1.2	4
300	Improving CAR T-Cell Persistence. International Journal of Molecular Sciences, 2021, 22, 10828.	4.1	44
301	Finding the volume dial in stem cell manufacturing: Bioinspired and bioengineered approaches to scale up. Current Opinion in Biomedical Engineering, 2021, 20, 100356.	3.4	0
302	Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 TÂcell effector differentiation. Cell Reports, 2021, 37, 109796.	6.4	14
303	Gene editing to enhance the efficacy of cancer cell therapies. Molecular Therapy, 2021, 29, 3153-3162.	8.2	5
304	Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models. Advanced Drug Delivery Reviews, 2021, 179, 114003.	13.7	20
307	Adding chimeric antigen receptor–induced killer cells to the medical oncology shelf. Journal of Clinical Investigation, 2019, 129, 5077-5078.	8.2	3
310	DNA Methylation in T-Cell Development and Differentiation. Critical Reviews in Immunology, 2020, 40, 135-156.	0.5	25
312	Quantification of cell-free DNA for the analysis of CD19-CAR-T cells during lymphoma treatment. Molecular Therapy - Methods and Clinical Development, 2021, 23, 539-550.	4.1	6
313	Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward. Frontiers in Immunology, 2021, 12, 765097.	4.8	20
315	Adaptive Immunity and the Tumor Microenvironment. Cancer Treatment and Research, 2020, 180, 111-147.	0.5	3
316	Cellular Therapy for Melanoma. , 2020, , 1267-1299.		0
319	Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. Current Research in Translational Medicine, 2022, 70, 103320.	1.8	9
320	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2022, 181, 114033.	13.7	5
321	Micro but mighty—Micronutrients in the epigenetic regulation of adaptive immune responses*. Immunological Reviews, 2021, , .	6.0	9
322	Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies. Journal of Personalized Medicine, 2021, 11, 1182.	2.5	2
324	Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Science Translational Medicine, 2021, 13, eabh0272.	12.4	123
325	Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. Blood, 2022, 139, 2156-2172.	1.4	33

#	ARTICLE	IF	CITATIONS
326	An NK-like CAR TÂcell transition in CAR TÂcell dysfunction. Cell, 2021, 184, 6081-6100.e26.	28.9	160
327	Mechanisms of Resistance and Relapse After CAR-T Cell Therapy. Cancer Drug Discovery and Development, 2022, , 207-219.	0.4	1
328	Clonal hematopoiesis: Molecular and clinical implications. Leukemia Research, 2022, 113, 106787.	0.8	15
330	Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy. Cancer Letters, 2022, 529, 139-152.	7.2	18
333	Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Advances, 2022, 6, 1941-1946.	5.2	21
335	Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer. Reviews in Medical Virology, 2022, 32, e2325.	8.3	6
336	Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies. Cytotherapy, 2022, 24, 405-412.	0.7	6
337	Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Antiâ€Leukemia Efficacy of CARâ€T Cells via SOCEâ€Calcineurinâ€NFAT and Glycolysis Pathways. Advanced Science, 2022, 9, e2103508.	11.2	21
338	CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 800110.	2.8	7
339	Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell, 2022, 185, 266-282.e15.	28.9	131
340	Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature, 2022, 602, 503-509.	27.8	369
341	Engineering CAR T cells for enhanced efficacy and safety. APL Bioengineering, 2022, 6, 011502.	6.2	14
342	Methods to monitor in vivo expansion and efficacy of CAR-T cells in preclinical models. Methods in Cell Biology, 2022, 167, 185-201.	1.1	0
343	CHIPâ€associated mutant ASXL1 in blood cells promotes solid tumor progression. Cancer Science, 2022, 113, 1182-1194.	3.9	17
344	Synthetic Biology-based Optimization of T cell Immunotherapies for Cancer. Current Opinion in Biomedical Engineering, 2022, 22, 100372.	3.4	0
345	Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy. Molecular Biology Reports, 2022, 49, 7069-7077.	2.3	9
346	Epigenetic regulation of inflammation by CxxC domainâ€containing proteins*. Immunological Reviews, 2022, 305, 137-151.	6.0	7
347	Epigenetics and CD8 ⁺ T cell memory*. Immunological Reviews, 2022, 305, 77-89.	6.0	22

		15	C
#	ARTICLE	IF	CITATIONS
348	Lymphoma. Frontiers in Genetics, 2022, 13, 826594.	2.3	6
349	Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials. Cancer Immunology, Immunotherapy, 2022, , 1.	4.2	5
350	PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine, 2022, 28, 724-734.	30.7	171
352	Tumor-intrinsic CD21 expression impacts the response of B-cell malignancy cells to CD19-CAR-T cells. Journal of Leukocyte Biology, 2022, 112, 913-918.	3.3	1
353	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood, 2022, 140, 16-24.	1.4	14
354	The Role of Ten-Eleven Translocation Proteins in Inflammation. Frontiers in Immunology, 2022, 13, 861351.	4.8	9
355	CAR TÂcells are in it [CD]4 the long haul. Cell, 2022, 185, 1112-1114.	28.9	1
356	Gene Editing for Inherited Red Blood Cell Diseases. Frontiers in Physiology, 2022, 13, 848261.	2.8	5
357	CD4 ⁺ chimeric antigen receptor T cells in for the long journey. Immunology and Cell Biology, 2022, 100, 304-307.	2.3	3
358	A decade of CAR T cell evolution. Nature Cancer, 2022, 3, 270-271.	13.2	12
359	TET2 regulates immune tolerance in chronically activated mast cells. JCI Insight, 2022, 7, .	5.0	4
360	Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy. Biomaterials, 2022, 286, 121510.	11.4	11
361	Epigenetic engineering empowers T cells. Blood, 2022, 139, 2091-2092.	1.4	0
362	Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials. Frontiers in Immunology, 2021, 12, 780145.	4.8	11
363	Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Molecular Cancer, 2021, 20, 171.	19.2	106
364	Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes. EJHaem, 2022, 3, 46-53.	1.0	3
365	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Frontiers of Medicine, 2021, 15, 783-804.	3.4	3
366	Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic. European Medical Journal (Chelmsford, England), 0, , .	3.0	0

		CITATION R	EPORT	
#	Article		IF	Citations
367	Inertial Microfluidic Purification of CARâ€Tâ€Cell Products. Advanced Biology, 2022, 6,	, 2101018.	2.5	2
369	NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Dev 2021, 10, 3390.	elopment. Cells,	4.1	17
370	Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. Current Treatment Optio 2022, 23, 171-187.	ns in Oncology,	3.0	9
371	Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Car of the National Cancer Institute, 2022, 114, 930-939.	ncer. Journal	6.3	10
372	Next-Generation CAR T-cell Therapies. Cancer Discovery, 2022, 12, 1625-1633.		9.4	53
373	Impact of Manufacturing Procedures on CAR T Cell Functionality. Frontiers in Immunol 876339.	ogy, 2022, 13,	4.8	54
375	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid le Cell, 2022, 40, 494-508.e5.	eukemia. Cancer	16.8	54
376	The mitochondrial pyruvate carrier regulates memory TÂcell differentiation and antitun Cell Metabolism, 2022, 34, 731-746.e9.	nor function.	16.2	63
378	T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktai Immunotherapy in Diffuse Large B-Cell Lymphoma. Frontiers in Immunology, 2022, 13,	l CAR T-Cell 873789.	4.8	4
379	A novel adoptive synthetic <scp>TCR</scp> and antigen receptor (<scp>STAR</scp>) therapy for <scp>B ell</scp> acute lymphoblastic leukemia. American Journal of He 992-1004.	<scp>Tâ€Cell</scp> matology, 2022, 97,	4.1	8
380	CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor curtailing cytokine release syndrome. Journal of Clinical Investigation, 2022, 132, .	responses while	8.2	66
381	Optimizing rAAV6 transduction of primary T cells for the generation of anti-CD19 AAV- Biomedicine and Pharmacotherapy, 2022, 150, 113027.	CAR-T cells.	5.6	2
382	Mechanisms of T cell exhaustion guiding next-generation immunotherapy. Trends in Ca 726-734.	ancer, 2022, 8,	7.4	18
383	Cross-linked actin networks (CLANs) affect stiffness and/or actin dynamics in transgen and primary human trabecular meshwork cells. Experimental Eye Research, 2022, 220,	ic transformed 109097.	2.6	4
384	Time to evolve: predicting engineered T cell-associated toxicity with next-generation m e003486.	odels. , 2022, 10,		21
386	Precision medicine: InÂvivo CAR therapy as a showcase for receptor-targeted vector pla Molecular Therapy, 2022, 30, 2401-2415.	atforms.	8.2	28
387	Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping Translational Oncology, 2022, 22, 101459.	strategies.	3.7	8
388	Epigenetic regulation of T cell exhaustion. Nature Immunology, 2022, 23, 848-860.		14.5	82

#	Article	IF	CITATIONS
390	Clonal hematopoiesis: Mutation-specific adaptation to environmental change. Cell Stem Cell, 2022, 29, 882-904.	11.1	34
391	Epiâ€immunotherapy for cancers: rationales of epiâ€drugs in combination with immunotherapy and advances in clinical trials. Cancer Communications, 2022, 42, 493-516.	9.2	14
392	Interpreting the B-cell receptor repertoire with single-cell gene expression using Benisse. Nature Machine Intelligence, 2022, 4, 596-604.	16.0	11
393	Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis. Cell Host and Microbe, 2022, 30, 1003-1019.e10.	11.0	24
394	The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity. Scientific Reports, 2022, 12, .	3.3	10
395	The Past, Present, and Future of Non-Viral CAR T Cells. Frontiers in Immunology, 0, 13, .	4.8	39
396	Genome-wide CRISPR screens of TÂcell exhaustion identify chromatin remodeling factors that limit TÂcell persistence. Cancer Cell, 2022, 40, 768-786.e7.	16.8	104
397	Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma. Blood Reviews, 2022, 56, 100986.	5.7	6
398	T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy. Frontiers in Immunology, 0, 13, .	4.8	2
399	Synthetic libraries of immune cells displaying a diverse repertoire of chimaeric antigen receptors as a potent cancer immunotherapy. Nature Biomedical Engineering, 2022, 6, 842-854.	22.5	4
400	Clinically Applicable Assessment of Tisagenlecleucel CAR T Cell Treatment by Digital Droplet PCR for Copy Number Variant Assessment. International Journal of Molecular Sciences, 2022, 23, 7573.	4.1	2
401	Safety of genetically modified T cells. Blood, 2022, 140, 1-2.	1.4	0
402	Genome-Edited T Cell Therapies. Hematology/Oncology Clinics of North America, 2022, 36, 729-744.	2.2	0
403	Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. Advanced Drug Delivery Reviews, 2022, 188, 114421.	13.7	18
404	Single-cell sorting based on secreted products for functionally defined cell therapies. Microsystems and Nanoengineering, 2022, 8, .	7.0	18
405	CAR T-cell Therapy Meets Clonal Hematopoiesis. Blood Cancer Discovery, 2022, 3, 382-384.	5.0	4
407	Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis. Haematologica, 2023, 108, 290-294.	3.5	4
408	CHIPing away the progression potential of CHIP: A new reality in the making. Blood Reviews, 2023, 58, 101001.	5.7	6

#	Article	IF	CITATIONS
409	Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity. Science Immunology, 2022, 7, .	11.9	8
410	Current progress in CAR‑T cell therapy for tumor treatment (Review). Oncology Letters, 2022, 24, .	1.8	7
411	Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL. Cancer Research Communications, 2022, 2, 1089-1103.	1.7	3
412	EZH1 repression generates mature iPSC-derived CAR TÂcells with enhanced antitumor activity. Cell Stem Cell, 2022, 29, 1181-1196.e6.	11.1	36
413	The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome. Seminars in Hematology, 2022, 59, 123-130.	3.4	7
414	Generation of T-cell-receptor-negative CD8 $\hat{i} \pm \hat{i}^2$ -positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature Biomedical Engineering, 2022, 6, 1284-1297.	22.5	27
415	Epigenetic engineering for optimal CARâ \in T cell therapy. Cancer Science, 0, , .	3.9	4
416	The steep uphill path leading to ex vivo gene therapy for genodermatoses. American Journal of Physiology - Cell Physiology, 2022, 323, C896-C906.	4.6	4
417	Potency monitoring of CAR T cells. Methods in Cell Biology, 2023, , 173-189.	1.1	1
419	Food and Drug Administration Guidance on Design of Clinical Trials for Gene Therapy Products with Potential for Genome Integration or Genome Editing and Associated Long-Term Follow-Up of Research Subjects. Applied Biosafety, 2022, 27, 201-209.	0.5	1
421	Exercise "CALM―and make CAR-T therapy work better. Science Bulletin, 2022, 67, 1925-1928.	9.0	2
422	Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	6
423	Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in chimeric antigen receptor T-cell products. Cytotherapy, 2023, 25, 94-102.	0.7	2
424	Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Science Translational Medicine, 2022, 14, .	12.4	52
426	Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine. Clinical Cancer Research, 2022, 28, 5306-5316.	7.0	4
427	Clinical application of cellâ€based therapies opportunities and challenges. Clinical and Translational Discovery, 2022, 2, .	0.5	0
428	INSERT-seq enables high-resolution mapping of genomically integrated DNA using Nanopore sequencing. Genome Biology, 2022, 23, .	8.8	7
429	Genome-edited allogeneic donor "universal―chimeric antigen receptor T cells. Blood, 2023, 141, 835-845.	1.4	11

#	Article	IF	CITATIONS
430	Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. Journal of Zhejiang University: Science B, 2022, 23, 793-811.	2.8	9
431	Clinical implications of T cell exhaustion for cancer immunotherapy. Nature Reviews Clinical Oncology, 2022, 19, 775-790.	27.6	182
432	Manufacturing next-generation regulatory T-cell therapies. Current Opinion in Biotechnology, 2022, 78, 102822.	6.6	8
434	Population dynamics and gene regulation of T cells in response to chronic antigen stimulation. International Immunology, 2023, 35, 67-77.	4.0	0
435	Clonal hematopoiesis and bone marrow inflammation. Translational Research, 2023, 255, 159-170.	5.0	3
436	Non-viral precision T cell receptor replacement for personalized cell therapy. Nature, 2023, 615, 687-696.	27.8	85
437	Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic Differentiation. Cancers, 2022, 14, 5576.	3.7	4
438	T Cells Directed against the Metastatic Driver Chondromodulin-1 in Ewing Sarcoma: Comparative Engineering with CRISPR/Cas9 vs. Retroviral Gene Transfer for Adoptive Transfer. Cancers, 2022, 14, 5485.	3.7	1
439	Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products. Journal of Translational Medicine, 2022, 20, .	4.4	11
440	Meeting FDA Guidance recommendations for replication-competent virus and insertional oncogenesis testing. Molecular Therapy - Methods and Clinical Development, 2023, 28, 28-39.	4.1	8
441	The future of engineered immune cell therapies. Science, 2022, 378, 853-858.	12.6	38
442	Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance. Frontiers in Immunology, 0, 13, .	4.8	6
443	RNA Therapeutics for Improving CAR T-cell Safety and Efficacy. Cancer Research, 2023, 83, 354-362.	0.9	6
444	Mammalian DNA methylome dynamics: mechanisms, functions and new frontiers. Development (Cambridge), 2022, 149, .	2.5	6
445	CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors. Clinical Cancer Research, 2023, 29, 1403-1411.	7.0	9
447	An evolved AAV variant enables efficient genetic engineering of murine TÂcells. Cell, 2023, 186, 446-460.e19.	28.9	17
448	TET Proteins in the Spotlight: Emerging Concepts of Epigenetic Regulation in T Cell Biology. ImmunoHorizons, 2023, 7, 106-115.	1.8	0
449	Molecular and therapeutic effect of CRISPR in treating cancer. , 2023, 40, .		2

	CITATION	Report	
#	Article	IF	CITATIONS
451	Clonal hematopoiesis and inflammation $\hat{a} \in$ the perpetual cycle. Trends in Cell Biology, 2023, 33, 695-707.	7.9	5
452	Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. Blood Cancer Journal, 2023, 13, .	6.2	8
453	Epigenetic Perspective of Immunotherapy for Cancers. Cells, 2023, 12, 365.	4.1	4
454	Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march. , 2023, , 97-131.		0
455	Advancing CAR T cell therapy through the use of multidimensional omics data. Nature Reviews Clinical Oncology, 2023, 20, 211-228.	27.6	30
456	Metabolic challenges and interventions in CAR T cell therapy. Science Immunology, 2023, 8, .	11.9	13
457	Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the <i>CD247 </i> locus. , 2023, 11, e005519.		2
458	Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review. Current Drug Research Reviews, 2023, 15, 241-261.	1.4	2
459	Clonal Hematopoiesis: Origins and determinants of evolution. Leukemia Research, 2023, 129, 107076.	0.8	2
460	Delivery of macromolecules in unstimulated T cells by photoporation with polydopamine nanoparticles. Journal of Controlled Release, 2023, 354, 680-693.	9.9	5
461	Massively parallel knock-in engineering of human T cells. Nature Biotechnology, 2023, 41, 1239-1255.	17.5	11
462	Germline T cell receptor exchange results in physiological T cell development and function. Nature Communications, 2023, 14, .	12.8	0
463	Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis. Cells, 2023, 12, 531.	4.1	1
464	TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature, 2023, 615, 315-322.	27.8	32
465	Challenges and opportunities of CAR T-cell therapies for CLL. Seminars in Hematology, 2023, 60, 25-33.	3.4	3
466	Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. Molecular Cancer, 2023, 22,	19.2	14
467	Gene-based delivery of immune-activating cytokines for cancer treatment. Trends in Molecular Medicine, 2023, 29, 329-342.	6.7	3
468	CAR immune cells: design principles, resistance and the next generation. Nature, 2023, 614, 635-648.	27.8	96

\sim		_	
	ΓΔΤΙ	ספאי	OPT
		INCLE.	

#	ARTICLE	IF	CITATIONS
469	Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability. , 2023, 11, e006119.		4
470	Challenges and optimal strategies of CAR T therapy for hematological malignancies. Chinese Medical Journal, 2023, 136, 269-279.	2.3	2
471	Integrative multi-omics approaches to explore immune cell functions: Challenges and opportunities. IScience, 2023, 26, 106359.	4.1	9
472	How I treat refractory/relapsed diffuse large Bâ€cell lymphomas with <scp>CD19</scp> â€directed <scp>chimeric antigen receptor</scp> T cells. British Journal of Haematology, 2023, 201, 396-410.	2.5	3
473	The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Frontiers in Immunology, 0, 14, .	4.8	23
474	Plasma proteomic and metabolomic signatures of Bâ€ALL patients during CARâ€∓ cell therapy. Clinical and Translational Medicine, 2023, 13, .	4.0	0
475	CLASH of the Titans: How CAR-T Cells Can Triumph Over Tumors. CRISPR Journal, 2023, 6, 87-89.	2.9	0
476	T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy. Trends in Immunology, 2023, 44, 397-398.	6.8	1
477	Advancing cell-based cancer immunotherapy through stem cell engineering. Cell Stem Cell, 2023, 30, 592-610.	11.1	14
478	T-cell engineering strategies for tumors with low antigen density, and T-cell survival in the immunosuppressive tumor microenvironment of relapsed/refractory diffuse large B-cell lymphoma. , 2023, 2, .		0
479	Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming. Cancers, 2023, 15, 1935.	3.7	2
480	Immunotherapy for Primary Cancers of Central Nervous System. , 2023, , 1-21.		0
481	Clonal haematopoiesis and dysregulation of the immune system. Nature Reviews Immunology, 2023, 23, 595-610.	22.7	18
482	Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion. Proceedings of the United States of America, 2023, 120, .	7.1	10
483	You've got a fast CAR. Science Immunology, 2023, 8, .	11.9	0
484	The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer. Nature Communications, 2023, 14, .	12.8	8
485	Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies. Annual Review of Cancer Biology, 2023, 7, 23-42.	4.5	1
486	Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade. , 2023, 11, e006930.		2

#	Article	IF	CITATIONS
487	Tagmentation-based analysis reveals the clonal behavior of CAR-T cells in association with lentivector integration sites. Molecular Therapy - Oncolytics, 2023, 30, 1-13.	4.4	0
488	Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology. Neoplasia, 2023, 42, 100909.	5.3	1
489	Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy. Frontiers in Immunology, 0, 14, .	4.8	1
490	Activation-inducible CAR expression enables precise control over engineered CAR T cell function. Communications Biology, 2023, 6, .	4.4	1
491	Massively parallel CRISPR off-target detection enables rapid off-target prediction model building. Med, 2023, 4, 478-492.e6.	4.4	2
492	Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction. Cancer Discovery, 2023, 13, 1636-1655.	9.4	4
493	The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ TÂcells. Immunity, 2023, 56, 1320-1340.e10.	14.3	8
494	Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface. JCO Precision Oncology, 2023, , .	3.0	1
496	TET2, tumor control, and CAR T cell hyperproliferation. Trends in Cancer, 2023, 9, 521-523.	7.4	0
497	Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	30
498	Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors. Immuno-Oncology Technology, 2023, 19, 100385.	0.3	1
499	Immune-based therapies in diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs, 2023, 32, 479-493.	4.1	1
500	Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. British Journal of Cancer, 2023, 129, 696-705.	6.4	2
501	Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies. Cancer Immunology Research, 2023, 11, 1030-1043.	3.4	0
502	Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies. Biomarker Research, 2023, 11, .	6.8	4
503	Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome. Leukemia, 2023, 37, 1868-1878.	7.2	2
504	Dual-locus, dual-HDR editing permits efficient generation of antigen-specific regulatory T cells with robust suppressive activity. Molecular Therapy, 2023, 31, 2872-2886.	8.2	1
505	Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies. Advances in Experimental Medicine and Biology, 2023, , 85-110.	1.6	0

#	Article	IF	CITATIONS
506	Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor Tâ€cells (CARâ€T): A comprehensive review on incidence, risk factors and current management. European Journal of Haematology, 2024, 112, 184-196.	2.2	3
507	Toward the clinical development of synthetic immunity to cancer. Immunological Reviews, 2023, 320, 83-99.	6.0	2
508	Coengineering specificity, safety, and function into T cells for cancer immunotherapy. Immunological Reviews, 2023, 320, 166-198.	6.0	3
509	H3K4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy. , 2023, 11, e005693.		0
510	Neurological adverse effects of chimeric antigen receptor T-cell therapy. Expert Review of Clinical Immunology, 2023, 19, 1361-1383.	3.0	3
511	Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell, 2023, 186, 4216-4234.e33.	28.9	2
512	Cellular and molecular waypoints along the path of T cell exhaustion. Science Immunology, 2023, 8, .	11.9	5
513	Optimization and validation of in vivo flow cytometry <scp>chimeric antigen receptor T</scp> cell detection method using <scp>CD19his</scp> indirect staining. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2024, 105, 112-123.	1.5	1
514	Challenges and new technologies in adoptive cell therapy. Journal of Hematology and Oncology, 2023, 16, .	17.0	12
515	TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells. Science Advances, 2023, 9, .	10.3	0
516	Glutarate regulates T cell metabolism and anti-tumour immunity. Nature Metabolism, 2023, 5, 1747-1764.	11.9	5
517	TET2 inhibits the proliferation and metastasis of lung adenocarcinoma cells via activation of the cGAS-STING signalling pathway. BMC Cancer, 2023, 23, .	2.6	1
518	Optimizing CAR-T Therapy for Glioblastoma. Molecular Diagnosis and Therapy, 2023, 27, 643-660.	3.8	1
519	Stem-like exhausted and memory CD8+ T cells in cancer. Nature Reviews Cancer, 2023, 23, 780-798.	28.4	5
520	CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. International Journal of Molecular Sciences, 2023, 24, 12317.	4.1	3
521	Longâ€ŧerm survivorship care after <scp>CARâ€₹</scp> cell therapy. European Journal of Haematology, 2024, 112, 41-50.	2.2	2
522	Innate immune response restarts adaptive immune response in tumors. Frontiers in Immunology, 0, 14, .	4.8	0
523	Genome Editing in Engineered T Cells for Cancer Immunotherapy. Human Gene Therapy, 2023, 34, 853-869.	2.7	1

#	Article	IF	CITATIONS
525	Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients. HemaSphere, 2023, 7, e957.	2.7	2
526	Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy. Immunity, 2023, 56, 2296-2310.	14.3	7
527	Cellular therapy in chronic lymphocytic leukemia: have we advanced in the last decade?. Acta Haematologica, 0, , .	1.4	2
528	Functional diversification and dynamics of CAR-T cells in patients with B-ALL. Cell Reports, 2023, 42, 113263.	6.4	1
529	Lipid nanoparticles outperform electroporation in mRNA-based CAR TÂcell engineering. Molecular Therapy - Methods and Clinical Development, 2023, 31, 101139.	4.1	4
530	INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies—Established Findings and Future Priorities. Transplantation and Cellular Therapy, 2024, 30, 155-170.	1.2	0
531	T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nature Reviews Drug Discovery, 2023, 22, 996-1017.	46.4	7
532	CAR-T Cell Therapy: From the Shop to Cancer Therapy. International Journal of Molecular Sciences, 2023, 24, 15688.	4.1	4
533	Successes and challenges in clinical gene therapy. Gene Therapy, 2023, 30, 738-746.	4.5	7
534	Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens. Nature Genetics, 2023, 55, 2211-2223.	21.4	3
535	Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer. Military Medical Research, 2023, 10, .	3.4	0
535 536	Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer. Military Medical Research, 2023, 10, . Photothermal nanofibers enable macromolecule delivery in unstimulated human T cells. Applied Materials Today, 2023, 35, 101991.	3.4 4.3	0
535 536 537	Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer. Military Medical Research, 2023, 10, . Photothermal nanofibers enable macromolecule delivery in unstimulated human T cells. Applied Materials Today, 2023, 35, 101991. Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. Military Medical Research, 2023, 10, .	3.4 4.3 3.4	0 0 1
535 536 537 538	Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer. Military Medical Research, 2023, 10, .Photothermal nanofibers enable macromolecule delivery in unstimulated human T cells. Applied Materials Today, 2023, 35, 101991.Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. Military Medical Research, 2023, 10, .Applications of singleâ€cell omics for chimeric antigen receptor <scp>T</scp> cell therapy. Immunology, 2024, 171, 339-364.	3.4 4.3 3.4 4.4	0 0 1
535 536 537 538 540	Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer.Military Medical Research, 2023, 10, .Photothermal nanofibers enable macromolecule delivery in unstimulated human T cells. AppliedMaterials Today, 2023, 35, 101991.Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. Military Medical Research, 2023, 10, .Applications of singleâ€cell omics for chimeric antigen receptor <scp>T</scp> cell therapy. Immunology, 2024, 171, 339-364. <i>SUV39H1</i> Ablation Enhances Long-term CAR T Function in Solid Tumors. Cancer Discovery, 2024, 14, 120-141.	 3.4 4.3 3.4 4.4 9.4 	0 0 1 1 3
535 536 537 538 540 541	Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer. Military Medical Research, 2023, 10, .Photothermal nanofibers enable macromolecule delivery in unstimulated human T cells. Applied Materials Today, 2023, 35, 101991.Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. Military Medical Research, 2023, 10, .Applications of singleâ€cell omics for chimeric antigen receptor <scp>T</scp> cell therapy. Immunology, 2024, 171, 339-364. <i>SUV39H1SUV39H1</i> >Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous TAcell therapy products. Molecular Therapy - Oncolytics, 2023, 31, 100749.	 3.4 4.3 3.4 4.4 9.4 4.4 	0 0 1 1 3 0
535 536 537 538 540 541	Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer. Military Medical Research, 2023, 10, .Photothermal nanofibers enable macromolecule delivery in unstimulated human T cells. Applied Materials Today, 2023, 35, 101991.Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. Military Medical Research, 2023, 10, .Applications of singleâCcell omics for chimeric antigen receptor <scp>T </scp> cell therapy. Immunology, 2024, 171, 339-364.SUN39H1 Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous TAcell therapy products. Molecular Therapy - Oncolytics, 2023, 31, 100749.Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation. Blood, 2024, 143, 872-881.	 3.4 4.3 3.4 4.4 9.4 4.4 1.4 	0 0 1 1 3 0

\sim	T . T	0.01	DEDODT
\sim	11/ 11		ICLI OICI

#	Article	IF	CITATIONS
545	Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells. Hematology American Society of Hematology Education Program, 2023, 2023, 91-96.	2.5	1
546	The intrinsic defects of T cells impact the efficacy of CAR-T therapy in patients with diffuse large B-cell lymphoma. Blood Cancer Journal, 2023, 13, .	6.2	0
547	Genetic retargeting of E3 ligases to enhance CAR TÂcell therapy. Cell Chemical Biology, 2024, 31, 338-348.e5.	5.2	1
548	Next-generation forward genetic screens: uniting high-throughput perturbations with single-cell analysis. Trends in Genetics, 2024, 40, 118-133.	6.7	0
549	Epigenome-Driven Strategies for Personalized Cancer Immunotherapy. Cancer Management and Research, 0, Volume 15, 1351-1367.	1.9	0
550	Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential. Frontiers in Oncology, 0, 13, .	2.8	0
551	Ten-Eleven-Translocation Genes in Cancer. Cancer Treatment and Research, 2023, , 363-373.	0.5	0
552	Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions. Cancers, 2024, 16, 46.	3.7	0
553	Epigenetic regulation in cancer therapy: From mechanisms to clinical advances. , 2024, 3, .		1
554	Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. Nature Communications, 2024, 15, .	12.8	0
555	SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors. , 2024, 21, 213-226.		1
556	Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma. Nature Communications, 2024, 15, .	12.8	0
557	Answering the "Doctor, can CAR-T therapy cause cancer?―question in clinic. Blood Advances, 2024, 8, 895-898.	5.2	2
559	CAR-T cell manufacturing: Major process parameters and next-generation strategies. Journal of Experimental Medicine, 2024, 221, .	8.5	0
560	The crossroads of cancer therapies and clonal hematopoiesis. Seminars in Hematology, 2024, 61, 16-21.	3.4	0
561	T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nature Medicine, 2024, 30, 984-989.	30.7	4
563	Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate. Journal of Medicinal Chemistry, 2024, 67, 4525-4540.	6.4	1
564	Per-cell histone acetylation is associated with terminal differentiation in human T cells. Clinical Epigenetics, 2024, 16, .	4.1	0

	CHATION R			
#	Article	IF	CITATIONS	
565	Naturally occurring T cell mutations enhance engineered T cell therapies. Nature, 2024, 626, 626-634.	27.8	2	
566	Cellular reprogramming by protein degradation: The next frontier in cancer immunotherapy. Cell Chemical Biology, 2024, 31, 189-192.	5.2	0	
567	Immune Cell Senescence and body Aging. Personalized Medicine Universe, 2023, 12, 1-7.	0.3	0	
568	Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies. International Journal of Molecular Sciences, 2024, 25, 2416.	4.1	0	
569	Genome editing approaches for universal chimeric antigen receptor T cells. , 2024, 3, 100149.		0	
571	A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human TÂcells. Cell, 2024, 187, 1278-1295.e20.	28.9	0	
572	Non-viral delivery of RNA for therapeutic T cell engineering. Advanced Drug Delivery Reviews, 2024, 208, 115215.	13.7	0	
573	Tumorâ€Associated Monocytes Reprogram CD8 ⁺ T Cells into Central Memory‣ike Cells with Potent Antitumor Effects. Advanced Science, 2024, 11, .	11.2	0	
574	Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy. Inflammation and Regeneration, 2024, 44, .	3.7	0	